Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Goodwill & Intangibles (2016 - 2025)

Coherus Oncology's Goodwill & Intangibles history spans 12 years, with the latest figure at $46.2 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 13.81% year-over-year to $46.2 million; the TTM value through Dec 2025 reached $46.2 million, down 13.81%, while the annual FY2025 figure was $46.2 million, 13.81% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $46.2 million at Coherus Oncology, up from $1.6 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $71.7 million in Q4 2023 and bottomed at $1.6 million in Q3 2025.
  • The 5-year median for Goodwill & Intangibles is $5.9 million (2022), against an average of $23.1 million.
  • The largest annual shift saw Goodwill & Intangibles skyrocketed 1108.45% in 2023 before it crashed 97.05% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $3.6 million in 2021, then skyrocketed by 66.46% to $5.9 million in 2022, then surged by 1108.45% to $71.7 million in 2023, then decreased by 25.15% to $53.6 million in 2024, then fell by 13.81% to $46.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Goodwill & Intangibles are $46.2 million (Q4 2025), $1.6 million (Q3 2025), and $53.0 million (Q1 2025).